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Inﬂammation, Atherosclerosis, Vascular Events, Aging, and Cancer*Serum lipoprotein-associated phospholipase A2 (Lp-PLA2) is an
established predictor of morbidity and mortality for cardiovascular
disease and stroke1. Lp-PLA2, also known as platelet-activating fac-
tor acetylhydrolase, is an enzyme involved in lipoprotein meta-
bolism and inﬂammatory responses2,3. It has atherogenic
properties and is extensively expressed by advanced atheroscle-
rotic lesions4.
In addition to cardiovascular disease, the plasma levels of Lp-
PLA2 have been shown to be signiﬁcantly increased in elderly pa-
tients when compared with the normal population5. Since oxida-
tive stress is implicated in the pathogenesis of atherosclerosis and
aging, and phospholipids are particularly sensitive to oxidative
stimuli, it is not surprising that elevated levels of Lp-PLA2, a facili-
tator to hydrolyze the oxidized phospholipids, were observed in
both situations.
Not only in aging and atherosclerotic lesions, several studies
have shown increased plasma levels of Lp-PLA2 in cancer pa-
tients6,7. In vivo deletion of the gene expressing Lp-PLA2 (Pla2g7)
in mice attenuates intestinal polyposis, suggesting that Lp-PLA2
may play a role in colon tumorigenesis6. Elevated Lp-PLA2 was
also demonstrated in patients with aggressive prostate cancer
and promoting cancer cell migration and invasion7.
Lp-PLA2 is not only a predictive marker for cardiovascular dis-
ease and stroke, but also a potential biomarker and putative thera-
peutic target for certain cancer. These diseases, although diverse
clinically, are all implicated by oxidative stress and elevated Lp-
PLA2. Given the increasing research interests on inﬂammatory tu-
mor microenvironments and cancer metabolism in the pathogen-
esis of tumor progression, whether Lp-PLA2 also comes in to play
with other proinﬂammatory molecules remains to be determined.* Conﬂict of interest: The author declares no conﬂict of interest.
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